|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2008.17.3567 on October 20 2008 © 2008 American Society of Clinical Oncology.
A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers
From the Department of Pathology, Yale University School of Medicine, New Haven, CT Corresponding author: David L. Rimm, MD, PhD, Department of Pathology, Yale University School of Medicine, 310 Cedar St, PO Box 208023, New Haven, CT 06520-8023; e-mail: david.rimm{at}yale.edu This year, 2008, marks the 10-year anniversary of the development of the modern tissue microarray (TMA). During the last decade, the use of TMAs has grown steadily and accounts for a small but increasing percentage of all cancer biomarker studies performed. The growing popularity of TMA-based studies attests to their benefits in the discovery and validation of new biomarkers. This review will focus on these benefits, but also on the faults of TMAs and the challenges of TMA studies that have been overcome in the last decade. We will also discuss the role of TMAs in the latest revolution in cancer treatment, the use of targeted drug therapy. published online ahead of print at www.jco.org on October 20, 2008. Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.
This article has been cited by other articles:
|
|||||||||||||
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|